Business Context and Reporting Period
This Form 8-K Current Report was filed by Vertex Pharmaceuticals Incorporated on August 27, 2026. The filing discloses a significant executive leadership change within the company's finance organization, effective January 1, 2027.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
- Executive Appointment: Jonathan Poole has been appointed as Executive Vice President and Chief Financial Officer, effective January 1, 2027.
- Role Transition: Charles F. Wagner, Jr. will cease serving as Chief Financial Officer on the effective date but will remain Executive Vice President and Chief Operating Officer.
- Compensation Structure: Mr. Poole's new role includes a base salary of $750,000 and a target annual bonus of 90% of base salary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of general business risks. It details specific contractual contingencies regarding Mr. Poole's employment:
- Termination Provisions: In the event of termination without cause or resignation for good reason, Mr. Poole is entitled to 100% of his base salary and target annual bonus for the year of termination, plus any earned but unpaid prior year bonus.
- Change of Control: Upon a change of control followed by termination without cause or for good reason, Mr. Poole receives 100% of base salary and target bonus, a pro-rated bonus, all earned cash incentives, and full vesting of outstanding equity awards (with performance criteria deemed achieved at target).
- Benefits: The company will cover COBRA premiums for up to 12 months following qualifying terminations.
Investor Verification Checklist
- Verify the exact effective date of the CFO transition (January 1, 2027) and the interim responsibilities of Charles F. Wagner, Jr.
- Review the full text of the employment and change of control agreements, which are scheduled to be filed as exhibits to the Form 10-Q for the quarter ended September 30, 2026.
- Confirm the total equity award value and specific performance metrics associated with Mr. Poole's new role, as these are not detailed in this summary.